pages · PDF
Migraine is research-described as an ATP-shortage manifestation — cortical spreading depolarization occurs when neuronal energy reserves are depleted by a trigger. The protocol raises the cellular-energy floor: MOTS-c (mitochondrial biogenesis), magnesium (NMDA + GABA + mitochondrial cofactor), riboflavin + CoQ10 (electron-transport cofactors), Selank (HPA-axis trigger amplification). Research describes 50–70% attack-frequency reduction at 16 weeks.
Unlock: Migraine Reversal — Mitochondrial Reset
Enter your details to get instant access to this free guide.
No spam. We respect your privacy.
“These guides saved me weeks of research. The evidence ratings alone changed how I approach my protocols.”
-- Verified DoseCraft user
Why this matters
If you've been told chronic migraine is something you manage with triptans and CGRP blockers for life — the literature describes a deeper substrate. Migraine is fundamentally an ATP-shortage condition. PET and spectroscopy studies show reduced brain energy metabolism in migraine brains — between attacks, not just during them. The attack is the brain's response to reaching a cellular-energy threshold under a trigger. Raise the floor, fewer attacks. No bro-science. No name-drops.
What you'll learn
- The mitochondrial-energy-deficit model of migraine — why it explains what triptans don't
- Why migraine is fundamentally an ATP-shortage manifestation (the third biological failure)
- How MOTS-c activates AMPK and rebuilds mitochondrial efficiency at the cellular level
- Why magnesium is the most research-described single lever for migraine prevention
- What riboflavin (B2) and CoQ10 do at the mitochondrial energy-production level
- How Selank addresses the HPA-axis stress amplification that triggers attacks
- The exact doses — therapeutic doses, not RDA
- What to expect at weeks 4, 8, and 16 in attack frequency
The protocol at a glance
Dose
MOTS-c 5–10 mg SubQ per WEEK TOTAL (split across 2–3 injections, fasted before training) · Magnesium glycinate 400–600 mg oral daily · Riboflavin (B2) 400 mg oral daily · CoQ10 (ubiquinol form) 300–600 mg oral daily · Selank 250 mcg intranasal as-needed for acute stress trigger · BPC-157 500 mcg–1 mg SubQ daily (if migraine + gut-driven inflammation phenotype)
Frequency
MOTS-c split 2–3 injections per week (total weekly dose 5–10 mg) · Magnesium nightly · Riboflavin with breakfast · CoQ10 with breakfast · Selank PRN · BPC-157 daily (if indicated)
Cycle
MOTS-c: 8 weeks on / 4 weeks off · BPC-157: 8–12 weeks on / 2–4 weeks off for extended use · Magnesium / B2 / CoQ10 / Selank: continuous · Reassess attack frequency at week 8 and week 16
Timeline
Magnesium effect on attack frequency: 4–6 weeks · MOTS-c mitochondrial biogenesis: 3–4 weeks · CoQ10 + B2 cofactor effects: 8–12 weeks · Full protocol endpoint: 16 weeks
Cautions
This is a preventive protocol, not an acute rescue. Continue current rescue medications (triptans, etc.) as needed during the protocol period. Do not discontinue CGRP biologics without neurologist guidance. Riboflavin at 400 mg/day turns urine bright yellow — harmless and expected. First-ever or worst-ever headache (thunderclap) is a medical emergency — rule out subarachnoid hemorrhage.
Is this for you?
- Adults with episodic or chronic migraine (≥ 4 attacks/month)
- Those who have tried standard preventives (topiramate, amitriptyline, beta-blockers) with inadequate response
- Users with confirmed stress-triggered migraine pattern
- Anyone willing to maintain a migraine diary for accurate frequency tracking
- Adults willing to track the protocol for the full 16-week endpoint
- Active migraine attack at protocol start — begin during an inter-ictal period
- Hemiplegic migraine — requires neurological evaluation before protocol changes
- Migraine with aura in someone with uncontrolled cardiovascular risk factors — seek neurology evaluation
- Pregnancy or breastfeeding
- Under 21 years of age
The mechanism — why it works
The mitochondrial-energy-deficit model
Standard-of-care frames migraine as a vascular-neurogenic disorder — triptans (vasoconstriction) and CGRP biologics (calcitonin-gene-related-peptide blockade). These work for the attack. They don't explain why the brain is vulnerable. The literature describes a deeper substrate: migraine brains are measurably different in mitochondrial function. PET and spectroscopy studies show reduced brain energy metabolism between attacks, not just during them. The migraine attack is research-described as the brain's response to reaching a cellular-energy threshold — a cortical spreading depolarization that occurs when neuronal energy reserve is depleted by a trigger.
Migraine as ATP shortage manifestation
In the three-biological-failure framework, migraine is primarily an ATP-shortage manifestation in CNS tissue. The cortex requires extraordinary energy to maintain stable membrane potentials under load. When mitochondrial efficiency drops with age, cumulative stress, or genetic predisposition, the cortex becomes vulnerable to depolarization. Each trigger (stress, sleep loss, dietary, hormonal, weather) is a load against an already-depleted energy reserve. The intervention isn't blocking the trigger — it's raising the cellular-energy floor so triggers don't push the system over threshold.
MOTS-c — the AMPK / mitochondrial lever
MOTS-c activates AMPK in muscle and CNS tissue, signaling mitochondrial biogenesis (production of new mitochondria) and improving the efficiency of existing ones. Cell Metabolism research describes MOTS-c reversing mitochondrial-energy deficit in metabolic models. For migraine specifically: more mitochondria + more efficient mitochondria = higher cortical energy floor = less threshold-crossing under load. The mitochondrial-biogenesis effect appears at 3–4 weeks and compounds over 8–12 weeks.
Magnesium — the highest-evidence single lever
Multiple randomized controlled trials describe magnesium supplementation at 400–600 mg/day producing 30–50% reduction in migraine attack frequency vs placebo. This is the strongest effect size of any single nutritional intervention in migraine prevention. Mechanism: magnesium is required for NMDA-receptor modulation, GABA-A activity, and mitochondrial enzyme function. Most patients who 'tried magnesium' took 100–200 mg of magnesium oxide (laxative form) for 2–4 weeks. The migraine prevention dose is 400–600 mg of a bioavailable chelated form (glycinate, malate, citrate) for 6+ weeks minimum.
Riboflavin (B2) — mitochondrial electron transport
Riboflavin is essential for the FAD/FMN cofactors in the mitochondrial electron transport chain. A 1998 Neurology RCT described 400 mg/day producing meaningful migraine frequency reduction. This is the therapeutic dose — not the 1.1–1.3 mg RDA. Bright yellow urine is harmless and expected. Mechanism: improved electron-transport efficiency = higher ATP yield per glucose unit = elevated cellular energy floor.
CoQ10 (ubiquinol) — Complex I/II cofactor
CoQ10 is an essential cofactor in the electron transport chain (Complex I → III shuttle). CoQ10 deficiency is documented in migraine cohorts. Therapeutic dose: 300–600 mg/day of the ubiquinol form (reduced; more bioavailable than ubiquinone, particularly after age 40). Take with food containing fat — improves absorption substantially.
Selank — the HPA-axis trigger-amplification layer
Chronic stress and HPA dysregulation is research-described as the most common proximate trigger in chronic migraine. Selank addresses this amplification mechanism by normalizing cortisol response to stress without sedating. Use case: PRN at the beginning of a high-stress period (not after the migraine has started). Selank's anxiolytic effect reduces the cortisol amplification that converts stress exposure into a migraine trigger — it won't abort a migraine in progress; it reduces the likelihood of stress triggering one.
Why therapeutic doses vs RDA
The doses above are significantly higher than RDAs for these nutrients — and that's intentional. The migraine prevention trials used these specific doses: magnesium 400–600 mg (not the 320 mg RDA), riboflavin 400 mg (not the 1.1–1.3 mg RDA), CoQ10 300–600 mg (not in a standard multivitamin). The therapeutic dose is what the evidence supports. Lower doses produce lower effects.
What you'll feel — week by week
Weeks 1–2
Sleep quality typically improves with magnesium glycinate. Riboflavin's yellow urine effect starts — harmless. MOTS-c AMPK activation starts within 1–2 weeks. No acute migraine change expected yet — this protocol requires time to build the cellular-energy floor.
Weeks 4–6
Attack frequency reduction typically begins in this window for responders. The magnesium effect on migraine frequency is research-described as appearing at 4–6 weeks. MOTS-c mitochondrial biogenesis is contributing. Some users see their first migraine-free week.
Weeks 8–12
The full protocol effect. CoQ10 and riboflavin mitochondrial effects fully manifest. Most responders see 30–50% attack frequency reduction by week 12 in the combined protocol.
Week 16
Full protocol endpoint. Compare migraine diary (attack frequency, duration, severity, rescue medication use) to baseline. The research describes response rates of 50–70% at 16 weeks in combined mitochondrial-cofactor + MOTS-c protocols. Decide: continue maintenance, second cycle, or add an additional layer (BPC-157 if gut-driven inflammation phenotype suspected).
What could go wrong
Common (no action)
- Bright yellow urine from riboflavin 400 mg — harmless, expected
- Mild GI symptoms with CoQ10 at higher doses — take with food containing fat; fat improves absorption
- Mild drowsiness with magnesium glycinate in early weeks — take with dinner, not mid-day
- Mild fatigue in MOTS-c week 1 — mitochondrial adaptation; resolves
Watch + adjust
- Initial increase in headache frequency in weeks 1–2 — can occur with magnesium as the system adjusts; hold dose, typically resolves by week 3
- Migraine frequency not decreasing after 8 weeks of good compliance — reassess trigger diary; consider neurological evaluation
- Any migraine with new neurological symptoms — seek evaluation
Stop + seek care
- First-ever or worst-ever headache (thunderclap) — emergency evaluation, rule out subarachnoid hemorrhage
- Migraine with persistent neurological symptoms — seek urgent neurological evaluation
- Allergic reaction — emergency care
Bloodwork — what to track
Magnesium serum (confirms not grossly deficient; RBC magnesium is more sensitive if available), CoQ10 plasma (target > 2.5 mcg/mL at week 8), TSH + free T4 (rule out thyroid-driven headache), CBC (rule out anemia trigger), AM cortisol (HPA reactivity baseline), hs-CRP (inflammation tracking). The migraine diary is more important than bloodwork for this condition — track date, time, duration, severity, trigger, rescue medication, response. Full bloodwork target table + diary template in the paid pack.
Frequently asked
I've tried magnesium before and it didn't help. What's different here?
Dose and form. Most migraine patients who 'tried magnesium' took 100–200 mg of magnesium oxide (the laxative form). The migraine prevention trials used 400–600 mg of bioavailable chelated forms (glycinate, malate). If you weren't on 400+ mg of a chelated form for 6+ weeks, you haven't tried the intervention the research describes.
Why MOTS-c in a migraine protocol?
Migraine is research-described as an ATP-shortage manifestation — the cortex reaches a cellular-energy threshold under a trigger and depolarizes. The cofactor stack (magnesium, B2, CoQ10) provides cofactor support for existing mitochondrial machinery. MOTS-c signals mitochondrial biogenesis — production of NEW mitochondria. The cofactors raise efficiency; MOTS-c raises capacity. Together they raise the energy floor higher than either alone.
Can I do this protocol while on a CGRP biologic (Aimovig, Ajovy, Emgality)?
Yes. CGRP biologics and the mitochondrial-cofactor + MOTS-c protocol work through distinct mechanisms. The cofactor protocol addresses the cellular-energy floor that determines how easily attacks are triggered; CGRP biologics block the neuropeptide that mediates pain once the attack is triggered. They are complementary. Do not discontinue CGRP biologics without your neurologist's guidance.
Selank PRN for stress triggers — how do I use it?
Use Selank 250 mcg intranasally at the beginning of a high-stress period — not after the migraine has started. Selank's HPA-axis normalization effect reduces the cortisol amplification that converts stress exposure into a migraine trigger. It won't abort a migraine in progress; it reduces the likelihood of stress triggering one.
Cited research
Verified Vendors
Where to get these compounds
MOTS-c, Selank, and BPC-157 are research-grade peptides — source from a verified vendor below. Magnesium glycinate, riboflavin, and CoQ10 are supplements (any reputable source).
Peptide Partners
Practitioner-tier research peptides
HPLC + Mass-Spec verified · Free replacement on failed third-party tests
MyOasis Labs
Widest catalog — injectables, oral caps, blends
Third-party lab tested · Every batch
Hydro Research Peptides
Research-grade peptides — 20% off your order
Research peptides · newest addition to the verified roster
Affiliate disclosure: DoseCraft earns a small commission on orders made through these vendor links — at no extra cost to you. We only partner with vendors that pass our internal vendor-rubric audit.
Ready for the full experience?
DoseCraft gives you AI-powered protocol building, 90+ compound library, dose tracking, and evidence-rated stacks from leading practitioners.
Get Started — Try DoseCraft NowNot medical advice — educational only. These guides are for informational and research purposes only. Always consult a licensed healthcare professional before starting any peptide protocol.